A patient presents with blurry vision for the past 6 months, decreased near vision in the left eye, and unilateral headaches. What should be in the list of differential diagnoses to ensure adequate management? Read this case report to find out more.
Do traumatic experiences contribute to the onset of tension headache? This authors of this study investigate this question and identify the defense styles that are more frequently used by patients with tension headache.
Most people with primary headache disorders, such as migraine, are undiagnosed. Read this PCC Supplement for updated classifications and assessments for patients with headache disorders and to identify and educate patients who are candidates for preventive treatment.
Episodic migraines often lead to medication-overuse headache. Anxiety, mood disorders, and disorders caused by psychoactive substances other than analgesics all have been reported in patients with medication-overuse headache. Could personality traits, anxiety and depressive disorders and headache type be related? Read this article to find out more.
Review results from a cross-sectional study of the prevalence of migraine headache among depressed Latino adults of Mexican American origin meeting the criteria for bipolar disorder or major depressive disorder relative to patients in a psychiatric comparison group.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”